Call it a series of unfortunate events, but manage

Quote:

---

Call it a series of unfortunate events, but management decisions over the past 5 years regarding financing/uplisting/deal-making, self-inflicted wounds

---

Yeah, and the BOD tried two different management styles. Tony Caracciolo took over in Jan 2017 to June 2018 and was in charge when the R/S debacle took place. Also, I suspect they probably also had several 80/20 split revenue offers usually BP will throw at small biotech, and have decided to push on themselves to get the 50/50. We will not know until the end if they chose wisely, I suspect they did looking at others taking the 80/20 splits.

https://www.cytodyn.com/newsroom/press-releas...ppointment

CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman

Quote:

---

In this new capacity, Mr. Caracciolo will assume an active leadership role in the Company’s strategic planning, business development and operations.
He has more than 38 years of experience in the pharmaceutical sciences industry. Previously, he served for 13 years at Gilead Sciences, Inc., a publicly traded research-based biopharmaceutical company, prior to his retirement in 2010. Among his positions at Gilead, he was Senior Vice President, Manufacturing and Operations, and a senior member of that company’s executive committee.

---